Sellas Life Sciences has achieved the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to measure the drug's efficacy, with preliminary results projected this quarter. Analysts warn that prolonged trial durations may enhance the likelihood of failure. The company continues to monitor the trial's progress closely, with updates anticipated as the trial advances. The REGAL trial is a significant step in the development of Galinpepimut-S, which has shown positive results in previous phases. Sellas Life Sciences remains dedicated on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's strategic approach to clinical trials and data analysis is greatly regarded in the industry, and investors are watching the trial's outcome with interest.